ArticleThe pharmacogenomics journal2026
Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study.
Article in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to assess the prevalence of the use of medications with pharmacogenomic guidelines upon hospital admission in patients aged 65 and over and evaluate its association with adverse outcomes, including length of stay, unplanned admissions, and repeat hospital admissions. A retrospective cross-sectional study was conducted using hospital admissions data from 2018-2019 in one NHS hospital trust in England, focusing on patients aged 65 and over. The usage of medications with pharmacogenomic guidelines was examined, and comparisons were made between their prevalence in unplanned and planned admissions. Multivariable models assessed whether the use of medications with pharmacogenomic guidelines were associated with adverse outcomes, considering frailty status. Analysis of 59,973 admissions revealed 67 pharmacogenomics medicines as per the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, with 11 classified as high-risk among 1438 unique medicines identified from 560,179 recorded medications. Notably, unplanned admissions exhibited a higher prevalence of medications with pharmacogenomic guidelines (84% versus 64%, p < 0.001) compared to planned admissions. The models demonstrated the usage of these medications was associated with adverse outcomes (length of stay in hospital, unplanned admission and repeat hospital admission) with substantial evidence (Delta_AICc < 2) particularly in patients with high frailty status. This study highlights the association between medications with pharmacogenomic guidelines and adverse outcomes, particularly among patients with high frailty. The findings emphasise the importance of integrating pharmacogenomic-guided care into the management of older individuals with frailty to mitigate adverse outcomes and enhance medication safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.